Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

This is a study to compare image quality between contrast and non-contrast cardiac MR and to
evaluate the diagnostic accuracy of a cardiac MRI procedure in a patient population that
includes both healthy volunteers and a study group of patients with known CAD who are
scheduled for clinical coronary angiography within one month of signing informed consent.
Both groups are eligible for a combination of imaging tests. Subjects may receive either a
non-contrast MRI or a contrast-enhanced MRI depending upon their kidney function and study
focus. Also based upon the focus of the study at the time of the scan and to improve image
quality, a beta-blocker to lessen motion artifact in patients with higher heart rates may be
administered or patients may be asked to undergo a stress test for comparison.This is a
one-day research procedure. Studies are acquired from the approved Institutional Review Board
#25881 Cedars-Sinai Biomedical Imaging Research Registry.

Inclusion:

- All subjects must be enrolled in the IRB approved Cedars-Sinai Biomedical Imaging
Research Registry where data is collected for this analysis study.

- Male or female ≥ 18years of age

- Healthy Group -No known CAD

- CAD Group-Scheduled for clinical invasive coronary artery x-ray angiography within one
month of study participation

Exclusion:

- MR imaging is contraindicated in persons with mechanically, magnetically, or
electrically activated implants, such as cardiac pacemakers, neurostimulators, and
infusion pumps.

- Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as
intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could
become dislodged.

- Patients who are pregnant, nursing are implanted with intrauterine devices (IUD's)

- Persons who are in atrial fibrillation at the time of the MR scan as this could result
in poor image quality due to interference with electrocardiographic gating necessary
for image acquisition.

- Persons unable to tolerate MRI imaging secondary to an inability to lie supine or
severe claustrophobia.

- Patient with renal failure (GFR< 45)

- Allergy to animal dander or animal-instigated asthma

- Specific to Ablavar: Baseline ECG measurements and concomitant medications will be
checked on subjects who are chosen to participate in the Ablavar study, based upon
study needs. If the ECG measurements and/or medications indicate that the subject is
at high risk for arrhythmia, the subject will be excluded from the Ablavar study, but
can participate in the OptiMark/MultiHance contrast study or non-contrast study.

- Specific to beta-blocker administration: no contraindication to beta blockers. If the
subject is found to have a contraindication to beta-blockers or declines the
administration of beta-blockers the subject will be excluded from the beta-blocker
portion but can still participate in a non-contrast or contrast-enhanced scan without
beta-blocker administration.

- Specific to Regadenoson: no contraindication to regadenoson administration. If the
subject is found to have a contraindication to regadenoson the subject will be
excluded from the regadenoson portion but can still participate in a non-contrast or
contrast-enhanced scan without regadenoson stress testing.

- Specific to Adenosine: no contraindication to adenosine administration.If the subject
is found to have a contraindication to adenosine the subject will be excluded from the
adenosine portion but can still participate in a non-contrast or contrast-enhanced
scan without adenosine stress testing.